Ramipril-associated lichen planus pemphigoides.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9115928.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the first case of lichen planus pemphigoides (LPP) secondary to ingestion of ramipril, an angiotensin-converting enzyme inhibitor. Clinical, histological and immunofluorescent findings were all consistent with a diagnosis of LPP. Linear basement membrane zone (BMZ) staining with IgG and C3 was only seen at the roof of split-skin preparations and circulating autoantibody to the BMZ was present at a titre of 1/100. Controlled immunoblotting of epidermal extracts detected the bullous pemphigoid antigens of 230 and 180 kDa.
Medical subject headings
- Angiotensin-Converting Enzyme Inhibitors
- Carrier Proteins
- Collagen
- Cytoskeletal Proteins
- Lichen Planus
- Nerve Tissue Proteins
- Non-Fibrillar Collagens
- Ramipril
- Skin Diseases, Vesiculobullous